Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05111145
Registration number
NCT05111145
Ethics application status
Date submitted
27/10/2021
Date registered
8/11/2021
Date last updated
11/07/2023
Titles & IDs
Public title
A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
Query!
Scientific title
A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis
Query!
Secondary ID [1]
0
0
2020-004885-21
Query!
Secondary ID [2]
0
0
VX20-445-121
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Cystic fibrosis
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ELX/TEZ/IVA
Treatment: Drugs - IVA
Experimental: ELX/TEZ/IVA - Participants received ELX 200 mg once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for up to 36 weeks.
Treatment: Drugs: ELX/TEZ/IVA
Fixed-dose combination tablets for oral administration.
Treatment: Drugs: IVA
Tablets for oral administration.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Day 1 up to Week 36
Query!
Eligibility
Key inclusion criteria
Key
- Completed study drug treatment in parent study (VX19-445-117 [NCT04599465] or
VX20-445-126 [NCT04969224]), or had study drug interruption(s) in parent study but
completed study visits up to the last scheduled visit of the treatment period in the
parent study
Key
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of drug intolerance in a parent study
Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/01/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/12/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
86
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [2]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [3]
0
0
Institute for Respiratory Health - Nedlands
Query!
Recruitment hospital [4]
0
0
Telethon Kids Institute - Nedlands
Query!
Recruitment hospital [5]
0
0
The Royal Children's Hospital - Parkville
Query!
Recruitment hospital [6]
0
0
Mater Adult Hospital - South Brisbane
Query!
Recruitment hospital [7]
0
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment postcode(s) [1]
0
0
- Chermside
Query!
Recruitment postcode(s) [2]
0
0
- Melbourne
Query!
Recruitment postcode(s) [3]
0
0
- Nedlands
Query!
Recruitment postcode(s) [4]
0
0
- Parkville
Query!
Recruitment postcode(s) [5]
0
0
- South Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Brussels
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Gent
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Leuven
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Calgary
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Edmonton
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Halifax
Query!
Country [7]
0
0
Czechia
Query!
State/province [7]
0
0
Brno
Query!
Country [8]
0
0
Czechia
Query!
State/province [8]
0
0
Praha 5
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Barcelona
Query!
Country [10]
0
0
Spain
Query!
State/province [10]
0
0
Madrid
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Murcia
Query!
Country [12]
0
0
Spain
Query!
State/province [12]
0
0
Sabadell
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Sevilla
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Vertex Pharmaceuticals Incorporated
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and tolerability of elexacaftor
(ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in participants with CF who are 12 years of age or
older.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05111145
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05111145
Download to PDF